Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.16)
# 2,820
Out of 5,172 analysts
41
Total ratings
48.65%
Success rate
-6.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $101 → $126 | $88.51 | +42.36% | 5 | Mar 4, 2026 | |
| ABBV AbbVie | Maintains: Outperform | $232 → $228 | $205.07 | +11.18% | 6 | Feb 5, 2026 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $38 → $36 | $17.56 | +105.01% | 1 | Dec 15, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $40.53 | +139.33% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $23.33 | +71.45% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $23.50 | +176.60% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $663.93 | +37.06% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.23 | +1,038.21% | 4 | Sep 22, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $1.54 | +224.68% | 1 | Apr 29, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.94 | +104.08% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $16.69 | +918.57% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $5.00 | +300.00% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $251.68 | -18.15% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $3.69 | +496.21% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.70 | +270.37% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $60.92 | -1.51% | 1 | Oct 5, 2022 |
Mirum Pharmaceuticals
Mar 4, 2026
Maintains: Outperform
Price Target: $101 → $126
Current: $88.51
Upside: +42.36%
AbbVie
Feb 5, 2026
Maintains: Outperform
Price Target: $232 → $228
Current: $205.07
Upside: +11.18%
Dyne Therapeutics
Dec 15, 2025
Maintains: Outperform
Price Target: $38 → $36
Current: $17.56
Upside: +105.01%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $40.53
Upside: +139.33%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $23.33
Upside: +71.45%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $23.50
Upside: +176.60%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $663.93
Upside: +37.06%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.23
Upside: +1,038.21%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.54
Upside: +224.68%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.94
Upside: +104.08%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $16.69
Upside: +918.57%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $5.00
Upside: +300.00%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $251.68
Upside: -18.15%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $3.69
Upside: +496.21%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.70
Upside: +270.37%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $60.92
Upside: -1.51%